NECFA
BDTX icon

New England Capital Financial Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

New England Capital Financial Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24
Closed -$46 – 399
2023
Q1 		$46 Hold
24
– – ﹤0.01% 429
2022
Q4 		$72 Buy
+24
New +$43 ﹤0.01% 430

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New England Capital Financial Advisors's BDTX Position: Q2 2023 in Review

New England Capital Financial Advisors sold out of Black Diamond Therapeutics (BDTX) in Q2 2023, closing a stake of 24 shares — an estimated $46 sold.

New England Capital Financial Advisors first reported a position in BDTX in Q4 2022 and held it in 2 quarters. The position peaked at $72 in Q4 2022. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2023.

  • New England Capital Financial Advisors reported no remaining Black Diamond Therapeutics position as of Q2 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 24 Black Diamond Therapeutics shares in Q2 2023, an estimated $46.
  • New England Capital Financial Advisors first reported a position in Black Diamond Therapeutics in Q4 2022 and held it in 2 quarters.
  • New England Capital Financial Advisors's Black Diamond Therapeutics position peaked at $72 in Q4 2022.
  • 74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2023.

Based on New England Capital Financial Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.